Interaction Between Abilify (Aripiprazole) and Reglan (Metoclopramide)
The combination of aripiprazole and metoclopramide should be avoided due to the significant risk of additive extrapyramidal symptoms (EPS), particularly tardive dyskinesia, and potentially opposing pharmacological effects on dopamine receptors.
Mechanism of Interaction
The interaction between these medications occurs through opposing dopaminergic effects:
- Aripiprazole is a partial dopamine D2 receptor agonist that modulates dopamine activity
- Metoclopramide is a dopamine D2 receptor antagonist that blocks dopamine receptors
When combined, these medications work against each other pharmacologically, potentially:
- Reducing the therapeutic efficacy of aripiprazole
- Increasing the risk of movement disorders through additive effects on the dopaminergic system
Primary Safety Concerns
Tardive Dyskinesia Risk
Both medications independently carry FDA black box warnings for tardive dyskinesia (TD), making their combination particularly hazardous 1:
- Metoclopramide causes TD with risk factors including longer duration of use (>12 weeks), older age, female sex, and diabetes
- The movements are often irreversible and include lip smacking, chewing, tongue protrusion, facial grimacing, and limb movements
- Risk increases exponentially when combining two agents that can cause TD 1
Research confirms metoclopramide produces TD rates comparable to typical antipsychotics in vulnerable populations 2.
Other Extrapyramidal Symptoms
The combination increases risk of:
- Acute dystonia (muscle spasms of face, neck, and body)
- Akathisia (severe restlessness)
- Parkinsonism (tremor, rigidity, bradykinesia)
- Neuroleptic Malignant Syndrome (rare but life-threatening)
These effects are documented for both medications individually 1 and would be expected to have additive risk when combined.
Clinical Recommendations
Avoid Concurrent Use
Do not prescribe these medications together. If a patient requires treatment for both conditions:
For GERD/gastroparesis: Consider alternative prokinetic agents that don't block dopamine receptors (e.g., domperidone where available, or non-pharmacologic approaches)
For nausea/vomiting: Use alternative antiemetics such as:
- Ondansetron (5-HT3 antagonist)
- Promethazine (with caution)
- Prochlorperazine (though this also has dopamine antagonism)
If metoclopramide is absolutely necessary: Consider temporarily holding aripiprazole or switching to an antipsychotic with a different mechanism
If Combination Cannot Be Avoided
Should clinical circumstances absolutely require both medications (rare):
- Limit metoclopramide duration to <12 weeks maximum 1
- Use the lowest effective doses of both agents
- Monitor closely for EPS at every visit using standardized scales
- Educate patients about TD warning signs and instruct them to report immediately
- Document informed consent about the increased risk
- Consider more frequent follow-up (weekly initially)
Common Pitfalls
- Failing to recognize metoclopramide as a dopamine antagonist: Many clinicians don't appreciate that metoclopramide has antipsychotic-like effects on the dopamine system
- Underestimating TD risk: TD can be permanent and disabling, affecting quality of life significantly
- Not checking for "hidden" metoclopramide: Patients may be taking metoclopramide prescribed by gastroenterologists without the psychiatrist's knowledge
- Ignoring the FDA's 12-week limit: Metoclopramide should never be used chronically 1
Monitoring Parameters
If the combination has already been initiated, immediately assess for:
- Abnormal involuntary movements (use AIMS scale)
- Muscle rigidity or spasms
- Restlessness or inability to sit still
- Changes in gait or tremor
- Reduced therapeutic effect of aripiprazole on psychiatric symptoms